Patients with severe COVID-19 exhibit higher levels of Gal-3, which are associated with increased inflammation, cytokine release, ARDS, and complications such as thrombosis, organ failure, and lung fibrosis [72]. The gene discussed is LGALS3; the disease is pulmonary fibrosis.